Overview

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Status:
Recruiting

Trial end date:
2023-10-05

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Cediranib
Durvalumab
Olaparib
Trastuzumab